| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Technion, Israel Institute of Technology Clalit Health Services |
| Information provided by: | Technion, Israel Institute of Technology |
| ClinicalTrials.gov Identifier: | NCT00448487 |
Purpose
3054 diabetic patients were screened for Haptoglobin Phenotype as part of the ICARE study (NCT00220831) and composite the I CARE Registry, 1434 Hp 2-2 patients were treated as part of the I CARE study with vitamin E vs. Placebo, this study was recently terminated due to significant differences between the groups and data was sent to publication. All other patients were passively followed since April 2005 for cardiovascular events. We have decided to continue and follow these patients till end of December 2007 to determine the incidence of CVD in theses patients which are pre stratified by Haptoglobin Phenotype.
| Condition |
|
Diabetes Cardiovascular Disease |
| MedlinePlus related topics: | Diabetes |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Prospective Observational Study to Asses the Incidence of CVD Complications in Diabetic Patients Pre-Stratified by Haptoglobin Phenotype From the I CARE Registry |
| Estimated Enrollment: | 3054 |
| Study Start Date: | April 2005 |
| Estimated Study Completion Date: | May 2008 |
3054 diabetic patients from Clalit Medical Services were screened for Haptoglobin Phenotype as part of the ICARE study (NCT00220831) and composite the I CARE registry, 1434 Hp 2-2 patients were treated as part of the I CARE study with vitamin E vs. Placebo, this study was recently terminated due to significant differences between the groups and data was sent to publication.
During the follow up period of the I CARE study all 3054 registry patients were followed in a passive way, which means that the patients were not called for follow up visits but the reports for CVD events were centrally collected from patient's Hospital admission summaries. Admission summaries were collected using the computerized systems of the Clalit Health Services assuring that when ever a patient in the registry is hospitalized for what ever reason the study coordination them would be aware of that and receive the admission summary. An events adjudication committee adjudicated each event in a blinded fashion to determine the nature of the events.
1434 patients who were treated by vitamin E or placebo in the I CARE study were also followed by follow-up telephone calls.
once I CARE study was officially terminated we have decided to continue and follow the whole 3054 registry patients in the same manner to complete a nearly 3 year follow up to determine in a prospective manner the incidence of CVD events in Diabetic patients which were pre-stratified by Haptoglobin type.
Eligibility
| Ages Eligible for Study: | 55 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
These are the same patients as in I CARE registry so the criteria are the same as was for I CARE study Recruitment phase.
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Israel | |||||
| Clalit Health Services, Haifa and Western Galilee District | |||||
| Haifa, Israel | |||||
| Technion, Israel Institute of Technology |
| Clalit Health Services |
| Principal Investigator: | Shany Blum, M.D. M.Sc. | Technion, Israel Institute of Technology |
| Principal Investigator: | Uzi Milman, M.D. | Clalit Health Services |
| Principal Investigator: | Chen Shapira, M.D. | Clalit Health Services |
| Principal Investigator: | Andrew P Levy, M.D. Ph.D. | Technion, Israel Institute of Technology |
More Information
| Study ID Numbers: | KL-2007 |
| First Received: | March 14, 2007 |
| Last Updated: | March 21, 2008 |
| ClinicalTrials.gov Identifier: | NCT00448487 |
| Health Authority: | Israel: Ministry of Health |
|
|
|
|
